Population pharmacokinetics and safety of solithromycin following intravenous and oral administration in infants, children, and adolescents

SOLI-PEDS Program

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Solithromycin is a novel fluoroketolide antibiotic which was under investigation for the treatment of community-acquired bacterial pneumonia (CABP). A phase 1 study was performed to characterize the pharmacokinetics (PK) and safety of solithromycin in children. Eighty-four subjects (median age, 6 years [age range, 4 days to 17 years]) were administered intravenous (i.v.) or oral (capsules or suspension) solithromycin (i.v., 6 to 8 mg/kg of body weight; capsules/suspension, 14 to 16 mg/kg on days 1 and 7 to 15 mg/kg on days 2 to 5). PK samples were collected after the first and multidose administration. Data from 83 subjects (662 samples) were combined with previously collected adolescent PK data (n 13; median age, 16 years [age range, 12 to 17 years]) following capsule administration to perform a population PK analysis. A 2-compartment PK model characterized the data well, and postmenstrual age was the only significant covariate after accounting for body size differences. Dosing simulations suggested that 8 mg/kg i.v. daily and oral dosing of 20 mg/kg on day 1 (800-mg adult maximum) followed by 10 mg/kg on days 2 to 5 (400-mg adult maximum) would achieve a pediatric solithromycin exposure consistent with the exposures observed in adults. Seventy-six treatment-emergent adverse events (TEAEs) were reported in 40 subjects. Diarrhea (6 subjects) and infusion site pain or phlebitis (3 subjects) were the most frequently reported adverse events related to treatment. Two subjects experienced TEAEs of increased hepatic enzymes that were deemed not to be related to the study treatment. (The phase 1 pediatric studies discussed in this paper have been registered at ClinicalTrials.gov under identifiers NCT01966055 and NCT02268279.)

Original languageEnglish (US)
Article numbere00692-18
JournalAntimicrobial Agents and Chemotherapy
Volume62
Issue number8
DOIs
StatePublished - Aug 1 2018

Fingerprint

Intravenous Administration
Oral Administration
Pharmacokinetics
Safety
Capsules
Population
Suspensions
Pediatrics
Therapeutics
Bacterial Pneumonia
Phlebitis
Body Size
Diarrhea
Body Weight
CEM 101
Anti-Bacterial Agents
Pain
Liver
Enzymes

Keywords

  • Antibiotics
  • Pediatrics
  • Pharmacokinetics
  • Safety
  • Solithromycin

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Population pharmacokinetics and safety of solithromycin following intravenous and oral administration in infants, children, and adolescents. / SOLI-PEDS Program.

In: Antimicrobial Agents and Chemotherapy, Vol. 62, No. 8, e00692-18, 01.08.2018.

Research output: Contribution to journalArticle

@article{f819c25ce0834fd39ad01f91179e894e,
title = "Population pharmacokinetics and safety of solithromycin following intravenous and oral administration in infants, children, and adolescents",
abstract = "Solithromycin is a novel fluoroketolide antibiotic which was under investigation for the treatment of community-acquired bacterial pneumonia (CABP). A phase 1 study was performed to characterize the pharmacokinetics (PK) and safety of solithromycin in children. Eighty-four subjects (median age, 6 years [age range, 4 days to 17 years]) were administered intravenous (i.v.) or oral (capsules or suspension) solithromycin (i.v., 6 to 8 mg/kg of body weight; capsules/suspension, 14 to 16 mg/kg on days 1 and 7 to 15 mg/kg on days 2 to 5). PK samples were collected after the first and multidose administration. Data from 83 subjects (662 samples) were combined with previously collected adolescent PK data (n 13; median age, 16 years [age range, 12 to 17 years]) following capsule administration to perform a population PK analysis. A 2-compartment PK model characterized the data well, and postmenstrual age was the only significant covariate after accounting for body size differences. Dosing simulations suggested that 8 mg/kg i.v. daily and oral dosing of 20 mg/kg on day 1 (800-mg adult maximum) followed by 10 mg/kg on days 2 to 5 (400-mg adult maximum) would achieve a pediatric solithromycin exposure consistent with the exposures observed in adults. Seventy-six treatment-emergent adverse events (TEAEs) were reported in 40 subjects. Diarrhea (6 subjects) and infusion site pain or phlebitis (3 subjects) were the most frequently reported adverse events related to treatment. Two subjects experienced TEAEs of increased hepatic enzymes that were deemed not to be related to the study treatment. (The phase 1 pediatric studies discussed in this paper have been registered at ClinicalTrials.gov under identifiers NCT01966055 and NCT02268279.)",
keywords = "Antibiotics, Pediatrics, Pharmacokinetics, Safety, Solithromycin",
author = "{SOLI-PEDS Program} and Daniel Gonzalez and James, {Laura P.} and Amira Al-Uzri and Miroslava Bosheva and Adler-Shohet, {Felice C.} and Mendley, {Susan R.} and Bradley, {John S.} and Claudia Espinosa and Eva Tsonkova and Kathryn Moffett and Lucila Marquez and Simonsen, {Kari A.} and Stefan Stoilov and Felix Boakye-Agyeman and Theresa Jasion and Hornik, {Christoph P.} and Robert Hernandez and Benjamin, {Daniel K.} and Michael Cohen-Wolkowiez",
year = "2018",
month = "8",
day = "1",
doi = "10.1128/AAC.00692-18",
language = "English (US)",
volume = "62",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "8",

}

TY - JOUR

T1 - Population pharmacokinetics and safety of solithromycin following intravenous and oral administration in infants, children, and adolescents

AU - SOLI-PEDS Program

AU - Gonzalez, Daniel

AU - James, Laura P.

AU - Al-Uzri, Amira

AU - Bosheva, Miroslava

AU - Adler-Shohet, Felice C.

AU - Mendley, Susan R.

AU - Bradley, John S.

AU - Espinosa, Claudia

AU - Tsonkova, Eva

AU - Moffett, Kathryn

AU - Marquez, Lucila

AU - Simonsen, Kari A.

AU - Stoilov, Stefan

AU - Boakye-Agyeman, Felix

AU - Jasion, Theresa

AU - Hornik, Christoph P.

AU - Hernandez, Robert

AU - Benjamin, Daniel K.

AU - Cohen-Wolkowiez, Michael

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Solithromycin is a novel fluoroketolide antibiotic which was under investigation for the treatment of community-acquired bacterial pneumonia (CABP). A phase 1 study was performed to characterize the pharmacokinetics (PK) and safety of solithromycin in children. Eighty-four subjects (median age, 6 years [age range, 4 days to 17 years]) were administered intravenous (i.v.) or oral (capsules or suspension) solithromycin (i.v., 6 to 8 mg/kg of body weight; capsules/suspension, 14 to 16 mg/kg on days 1 and 7 to 15 mg/kg on days 2 to 5). PK samples were collected after the first and multidose administration. Data from 83 subjects (662 samples) were combined with previously collected adolescent PK data (n 13; median age, 16 years [age range, 12 to 17 years]) following capsule administration to perform a population PK analysis. A 2-compartment PK model characterized the data well, and postmenstrual age was the only significant covariate after accounting for body size differences. Dosing simulations suggested that 8 mg/kg i.v. daily and oral dosing of 20 mg/kg on day 1 (800-mg adult maximum) followed by 10 mg/kg on days 2 to 5 (400-mg adult maximum) would achieve a pediatric solithromycin exposure consistent with the exposures observed in adults. Seventy-six treatment-emergent adverse events (TEAEs) were reported in 40 subjects. Diarrhea (6 subjects) and infusion site pain or phlebitis (3 subjects) were the most frequently reported adverse events related to treatment. Two subjects experienced TEAEs of increased hepatic enzymes that were deemed not to be related to the study treatment. (The phase 1 pediatric studies discussed in this paper have been registered at ClinicalTrials.gov under identifiers NCT01966055 and NCT02268279.)

AB - Solithromycin is a novel fluoroketolide antibiotic which was under investigation for the treatment of community-acquired bacterial pneumonia (CABP). A phase 1 study was performed to characterize the pharmacokinetics (PK) and safety of solithromycin in children. Eighty-four subjects (median age, 6 years [age range, 4 days to 17 years]) were administered intravenous (i.v.) or oral (capsules or suspension) solithromycin (i.v., 6 to 8 mg/kg of body weight; capsules/suspension, 14 to 16 mg/kg on days 1 and 7 to 15 mg/kg on days 2 to 5). PK samples were collected after the first and multidose administration. Data from 83 subjects (662 samples) were combined with previously collected adolescent PK data (n 13; median age, 16 years [age range, 12 to 17 years]) following capsule administration to perform a population PK analysis. A 2-compartment PK model characterized the data well, and postmenstrual age was the only significant covariate after accounting for body size differences. Dosing simulations suggested that 8 mg/kg i.v. daily and oral dosing of 20 mg/kg on day 1 (800-mg adult maximum) followed by 10 mg/kg on days 2 to 5 (400-mg adult maximum) would achieve a pediatric solithromycin exposure consistent with the exposures observed in adults. Seventy-six treatment-emergent adverse events (TEAEs) were reported in 40 subjects. Diarrhea (6 subjects) and infusion site pain or phlebitis (3 subjects) were the most frequently reported adverse events related to treatment. Two subjects experienced TEAEs of increased hepatic enzymes that were deemed not to be related to the study treatment. (The phase 1 pediatric studies discussed in this paper have been registered at ClinicalTrials.gov under identifiers NCT01966055 and NCT02268279.)

KW - Antibiotics

KW - Pediatrics

KW - Pharmacokinetics

KW - Safety

KW - Solithromycin

UR - http://www.scopus.com/inward/record.url?scp=85052020696&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052020696&partnerID=8YFLogxK

U2 - 10.1128/AAC.00692-18

DO - 10.1128/AAC.00692-18

M3 - Article

C2 - 29891609

AN - SCOPUS:85052020696

VL - 62

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 8

M1 - e00692-18

ER -